Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F OFFNER

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Leukemia|March 25, 2018
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY studyS Rule, W Jurczak, M Jerkeman, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica|October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myelomaR Schots, M Delforge, M André, et al.
Gut|July 18, 2000
The Vienna classification of gastrointestinal epithelial neoplasiaR J Schlemper, R H Riddell, Y Kato, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Leukemia|March 25, 2018
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY studyS Rule, W Jurczak, M Jerkeman, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica|October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myelomaR Schots, M Delforge, M André, et al.
Gut|July 18, 2000
The Vienna classification of gastrointestinal epithelial neoplasiaR J Schlemper, R H Riddell, Y Kato, et al.
Pageof 10